JP2011511789A5 - - Google Patents

Download PDF

Info

Publication number
JP2011511789A5
JP2011511789A5 JP2010545893A JP2010545893A JP2011511789A5 JP 2011511789 A5 JP2011511789 A5 JP 2011511789A5 JP 2010545893 A JP2010545893 A JP 2010545893A JP 2010545893 A JP2010545893 A JP 2010545893A JP 2011511789 A5 JP2011511789 A5 JP 2011511789A5
Authority
JP
Japan
Prior art keywords
composition
cis
retinyl
synthetic retinal
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010545893A
Other languages
English (en)
Japanese (ja)
Other versions
JP6022746B2 (ja
JP2011511789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000824 external-priority patent/WO2009102418A1/en
Publication of JP2011511789A publication Critical patent/JP2011511789A/ja
Publication of JP2011511789A5 publication Critical patent/JP2011511789A5/ja
Application granted granted Critical
Publication of JP6022746B2 publication Critical patent/JP6022746B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010545893A 2008-02-11 2009-02-10 加齢関連性網膜機能不全の治療及び予防方法 Expired - Fee Related JP6022746B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2762508P 2008-02-11 2008-02-11
US61/027,625 2008-02-11
PCT/US2009/000824 WO2009102418A1 (en) 2008-02-11 2009-02-10 Methods for the treatment and prevention of age-related retinal dysfunction

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014157921A Division JP5934304B2 (ja) 2008-02-11 2014-08-01 加齢関連性網膜機能不全の治療及び予防方法
JP2016094767A Division JP6272943B2 (ja) 2008-02-11 2016-05-10 加齢関連性網膜機能不全の治療及び予防方法

Publications (3)

Publication Number Publication Date
JP2011511789A JP2011511789A (ja) 2011-04-14
JP2011511789A5 true JP2011511789A5 (https=) 2012-04-05
JP6022746B2 JP6022746B2 (ja) 2016-11-09

Family

ID=40521846

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010545893A Expired - Fee Related JP6022746B2 (ja) 2008-02-11 2009-02-10 加齢関連性網膜機能不全の治療及び予防方法
JP2014157921A Active JP5934304B2 (ja) 2008-02-11 2014-08-01 加齢関連性網膜機能不全の治療及び予防方法
JP2016094767A Expired - Fee Related JP6272943B2 (ja) 2008-02-11 2016-05-10 加齢関連性網膜機能不全の治療及び予防方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014157921A Active JP5934304B2 (ja) 2008-02-11 2014-08-01 加齢関連性網膜機能不全の治療及び予防方法
JP2016094767A Expired - Fee Related JP6272943B2 (ja) 2008-02-11 2016-05-10 加齢関連性網膜機能不全の治療及び予防方法

Country Status (14)

Country Link
US (7) US8324270B2 (https=)
EP (1) EP2252276B1 (https=)
JP (3) JP6022746B2 (https=)
KR (2) KR101810381B1 (https=)
CN (1) CN101969938A (https=)
AU (1) AU2009213138B2 (https=)
BR (1) BRPI0908154A2 (https=)
CA (2) CA3018374A1 (https=)
IL (2) IL207220B (https=)
MX (1) MX337656B (https=)
NZ (3) NZ587376A (https=)
RU (1) RU2565448C2 (https=)
WO (1) WO2009102418A1 (https=)
ZA (1) ZA201005434B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
NZ587006A (en) 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
WO2009102418A1 (en) * 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
CN102612375B (zh) * 2009-09-15 2016-01-27 Qlt股份有限公司 含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
CN107308143A (zh) * 2010-04-19 2017-11-03 诺维利昂治疗股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
US10226536B2 (en) 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
JP6576636B2 (ja) * 2012-03-01 2019-09-18 ノベリオン セラピューティクス インコーポレイテッド 内因性レチノイド欠乏に関連する視覚障害における視覚機能を改善するための治療的計画および方法
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
CA3054811A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
WO2021062022A1 (en) * 2019-09-25 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN116056691A (zh) * 2020-06-09 2023-05-02 典晶生物医药科技(苏州)有限公司 使用每日低剂量的类视黄醇化合物治疗视觉障碍的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196076A (en) 1961-12-20 1965-07-20 Schering Corp Anti-depressant 10-(3-dimethylaminopropyl)-3-azaphenothiazine
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
NZ283658A (en) 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) * 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
WO2000068354A1 (en) 1999-05-07 2000-11-16 Chemlink Laboratories Llc Window cleaner tablet
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
CN1455780A (zh) 2001-01-11 2003-11-12 株式会社开备传 新视黄醇衍生物、其制备方法和用途
CA2435410A1 (en) 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
AU2003210597A1 (en) 2002-01-18 2003-07-30 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
WO2003082081A2 (en) 2002-03-29 2003-10-09 Maxim Pharmaceuticals, Inc. Use of rom production and release inhibitors to treat and prevent intraocular damage
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
US20080176952A1 (en) 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2601278C (en) 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
NZ587006A (en) * 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
AU2005287343A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
US20080275133A1 (en) 2004-09-30 2008-11-06 University Of Calfornia-San Francisco Local Administration of Retinoids to Treat Deficiencies in Dark Adaptation
WO2009035673A1 (en) 2007-09-12 2009-03-19 Trustees Of Columbia University In The City Of Newyork Compositions and methods for treating macular degeneration
WO2009102418A1 (en) 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction

Similar Documents

Publication Publication Date Title
JP2011511789A5 (https=)
RU2011139643A (ru) Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
JP2018514534A5 (https=)
US20080089861A1 (en) Combination therapy for treatment of demyelinating conditions
NZ600498A (en) Methods for the treatment and prevention of age-related retinal dysfunction
JP2012520866A5 (https=)
JP2010518122A5 (https=)
RU2004123637A (ru) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
JP2018520189A5 (https=)
JP2008189635A (ja) 疼痛疾患治療剤
EA022631B1 (ru) Лекарственная форма, содержащая масляную кислоту или глутамин, и способ лечения состояния с повышенным уровнем глюкозы у субъекта
AU2012250877B2 (en) Composition and method for treatment of diabetes
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
JP2005513107A5 (https=)
US20100004203A1 (en) Medicament for preventive and/or therapeutic treatment of bowel disease
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2012502047A5 (https=)
US20160184252A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
CN110314233B (zh) 包含柠檬苦素类化合物和dpp-4抑制剂的组合产品
WO2019029319A1 (zh) 包含柠檬苦素类化合物和双胍类化合物的组合产品
CA2788865A1 (en) Composition comprising as active ingredient l-carnitine in combination with hydroxykynurenine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
JP2009506978A5 (https=)
WO2021027582A1 (zh) 包含柠檬苦素类化合物和噻唑烷二酮类药物的组合产品
EP2293790A2 (fr) Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs
WO2016138103A1 (en) Treatments for alzheimer's related diseases and disorders